Thermo Fisher Scientific provides analytical instruments, equipment, reagents and consumables, software, and services for research, manufacturing, analysis, discovery, and diagnostics worldwide. The company was founded in 1956 and is based in Waltham, Massachusetts.
TMO Price Forecast Based on DCF Valuation
DCF Fair Value Target:
We started the process of determining a valid price forecast for Thermo Fisher Scientific Inc with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that Thermo Fisher Scientific Inc ranked in the 23th percentile in terms of potential gain offered. We should note, though, that all scenearios modelled for this stock suggest it is overvalued. As for the metrics that stood out in our discounted cash flow analysis of Thermo Fisher Scientific Inc, consider:
The company's balance sheet shows it gets 90% of its capital from equity, and 10% of its capital from debt. Its equity weight surpasses that of 61% of free cash flow generating stocks in the Healthcare sector.
The business' balance sheet reveals debt to be 10% of the company's capital (with equity being the remaining amount). Approximately merely 24.13% of US stocks with free cash flow have a lower reliance on debt in their capital structure.
Terminal Growth Rate in Free Cash Flow
Return Relative to Current Share Price
REPH, BAX, GMED, MDT, and OFIX can be thought of as valuation peers to TMO, in the sense that they are in the Healthcare sector and have a similar price forecast based on DCF valuation.
DBMR has added a new report titled Anti-Nuclear Antibody Test Market with analysis provides the insights which bring marketplace clearly into the focus and thus help organizations make better decisions. The data and the information regarding the industry are taken
A report by The Insight Partner's on the Immunohistochemistry Market discusses the growth of the market in great detail. It discusses thoroughly all factors promoting and deterring the market. The report also focuses on the competitive dynamics in the market
Data Bridge Market Research has recently added a concise research on the Clinical Oncology Next Generation Sequencing Market to depict valuable insights related to significant market trends driving the industry. The report features analysis based on key opportunities and challenges
A new business intelligence report released by HTF MI with title "COVID-19 Outbreak-Global Drug Discovery Services Industry Market Report-Development Trends, Threats, Opportunities and Competitive Landscape in 2020" is designed covering micro level of analysis by manufacturers and key business segments.
The latest study on the Bioburden Testing market published by the Reports and Data offers a deep understanding of the various market dynamics such as the challenges, drivers, trends, and opportunities. The report further elaborates on the micro and macro-economic